)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Japan Lifeline
Japan Lifeline (7575) investor relations material
Japan Lifeline Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary30 Oct, 2026
Executive summary
H1 FY2027 net sales set a six-month record at ¥31,353mn, up 7.1% YoY; operating profit fell 17.4% to ¥5,468mn and net income fell 7.2% to ¥4,430mn.
EP/Ablation and newer Neurovascular and Gastrointestinal businesses offset lower CRM sales; higher R&D and other SG&A weighed on profit.
Financial highlights
H1 net sales rose ¥2,068mn to ¥31,353mn; proprietary products grew 11.0% YoY and procured products 2.0%.
Gross profit increased 2.6% to ¥18,018mn, while SG&A rose 14.8% to ¥12,550mn; operating profit declined to ¥5,468mn.
Q2 sales set a record at ¥15,449mn, up 5.3% YoY; operating profit fell 25.2% to ¥2,502mn and net income fell 14.2% to ¥2,120mn.
Ordinary profit decreased 8.8% to ¥6,040mn; non-operating income included a ¥367mn securities valuation gain and ¥203mn bad-debt allowance reversal, while extraordinary income included a ¥346mn securities-sale gain.
Basic EPS was ¥63.15 versus ¥68.08 YoY; comprehensive income was ¥4,254mn versus ¥4,667mn.
Outlook and guidance
FY2027 guidance unchanged: net sales ¥63,200mn, operating profit ¥10,700mn, ordinary profit ¥10,800mn and net income ¥8,000mn; H1 attained 49.6%, 51.1%, 55.9% and 55.4%, respectively.
H1 profit exceeded plan mainly because R&D expenses were delayed; most are expected from Q3 onward, with full-year profit generally expected to remain in line with guidance.
Management expects sales generally in line with guidance from Q3 onward; CRM weakness is expected to continue, while EP/Ablation, Neurovascular and Gastrointestinal sales are expected to expand.
FY2028 mid-term plan forecast is ¥68.0bn sales and ¥7.0bn operating profit, below targets of ¥70.0bn and ¥11.0bn; cited factors include delayed TAVI launch and accelerated R&D investment.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Japan Lifeline
- Record sales rose 8.8% YoY, with strong segment growth and a raised dividend forecast.7575
Q1 2027 - Record sales and profits, but FY2027 profit to dip on higher costs and investments.7575Q4 2026
- Record nine-month sales; profits declined amid one-time costs and PFA pressure, with guidance unchanged.7575Q3 2026
- Record H1 sales and profits, led by core and high-growth segments, with guidance on track.7575Q2 2026
- Sales and operating profit grew, but net profit dipped amid strong segment gains and market shifts.7575Q1 2026
- Record sales and profit growth led by EP/Ablation and new product launches.7575Q2 2025
- Record-high quarterly results led by EP/ablation and neurovascular growth, guidance maintained.7575Q1 2025
- Record FY 2025 results underpin higher targets and structural-heart, PFA and global growth plans.7575Q4 2025
- Record 9M growth drove higher FY25 guidance amid Q4 cost and reimbursement pressures.7575Q3 2025
Next Japan Lifeline earnings date
Q3 202729 Jan, 2027
Japan Lifeline
Next Japan Lifeline earnings date
Q3 202729 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Japan Lifeline Co., Ltd., commonly known as Japan Lifeline, is a medical device company based in Japan. It specializes in the development, production, importation, and distribution of medical devices focused primarily on cardiovascular healthcare. The company offers a wide range of products, including cardiac rhythm management devices such as cardiac pacemakers and implantable cardioverter defibrillators, as well as electrophysiology and ablation products. Additionally, Japan Lifeline provides cardiovascular and endografting products, such as vascular stents and grafts, and various intervention products like PTCA balloon catheters and guide wires. It is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.